1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Ambu A/S

Ambu A/S

AMBBY
Ambu A/SUS flagOther OTC
10.51
USD
- -
- -
2.79BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.91
6.68
7.86
8.79
9.94
10.72
11.54
14.47
15.94
17.5
18.33
20.24
- -
22.36
Basic EPS, GAAP
0.2
0.64
0.63
1.05
1.27
1.39
1.3
0.98
0.98
0.37
0.64
0.88
- -
1.35
Free Cash Flow per Basic Share
0.52
0.73
0.87
1.31
1.95
1.31
1.11
-0.55
-1.02
-1.8
0.74
1.97
- -
1.41
Dividend per Share
0.15
0.06
0.19
0.19
0.32
0.38
0.41
0.39
0.29
0.3
- -
- -
- -
0.38
Book Value per Share
2.73
3.2
3.47
3.17
4.5
6.96
7.9
9.03
14.98
15.28
19.89
20.46
- -
22.02
Tangible Book Value per Share
-1.16
-0.62
-0.21
-1.05
0.27
-3.12
-2.48
-2.28
2.81
2.53
6.84
8.88
- -
10.02
Basic Weighted Avg Shares
234
237
240
237
237
243
244
247
252
254
260
266
267
267
Sales/Revenue/Turnover
1,383
1,584
1,889
2,084
2,355
2,606
2,820
3,567
4,013
4,444
4,775
5,391
- -
5,958
Operating Margin (%)
11.42
12.5
12.76
17.08
19.53
21.6
17.02
12
8.47
2.75
6.32
11.96
- -
13.16
Depreciation Expense
74
88
96
102
105
115
109
181
216
351
348
696
- -
704
Net Income, GAAP
48
151
152
250
301
337
317
241
247
93
168
235
- -
359
Effective Tax Rate (%)
31.43
27.4
29.3
23.31
23.41
27.53
23.24
25.16
19.81
14.68
20
21.67
- -
15.33
Profit Margin (%)
3.47
9.53
8.05
12
12.78
12.93
11.24
6.76
6.15
2.09
3.52
4.36
- -
6.03
Working Capital
298
351
400
381
-284
511
154
197
628
1,143
1,066
1,578
- -
1,929
LT Debt
753
702
700
925
83
1,304
1,151
1,401
760
1,766
512
483
- -
459
Total Equity
651
854
1,036
990
1,279
1,882
2,182
2,372
3,952
4,261
5,393
5,594
- -
5,905
Return on Invested Capital (%)
9.73
9.07
9.46
13.94
17.13
15.29
11.06
8.91
6.37
1.91
4.01
8.32
- -
10.32
Return on Capital (%)
5.83
11.92
10.8
16.28
18.15
14.81
10.92
7.75
6.48
2.33
3.77
4.35
- -
6.28
Return on Common Equity (%)
7.69
21.62
19.11
31.55
33.1
24.43
17.49
11.59
8.24
2.43
3.71
4.42
- -
6.28

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'25
ST Debt
75
76
75
LT Borrowings
- -
- -
- -
LT Finance Leases
489
478
459
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
266
266
266
Market Capitalization
25,130
31,413
26,307

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'25
Total Current Assets
2,808
2,891
2,943
Cash, Cash Equivalents & STI
588
640
751
Accounts Receivable, Net
826
877
852
Inventories
1,228
1,214
1,193
Total Current Liabilities
1,078
1,003
1,014
Payables & Accruals
- -
- -
- -
ST Debt
75
76
75
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,254
1,367
1,383
1,387
5,391
2025
1,510
1,554
1,507
- -
- -
2026
1,558
1,573
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.54
0.5
-0.51
0.88
2025
0.68
0.71
0.46
- -
- -
2026
0.44
0.46
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.3
0.08
- -
- -
- -
2026
0.34
0.08
- -
- -
- -

Company Description

APIChatGPT
CEO
Britt Meelby Jensen
Full Time Employees
5,292
Sector
Healthcare
Industry
Medical - Devices
Address
Baltorpbakken 13 Ballerup CR Denmark 2750
IPO Date
Jan 8, 2021
Website
ambu.com
Similar Companies
Abbott Laboratories (ABT)
Bonesupport Holding AB (publ) (2B4.F)
Nexalin Technology, Inc. (NXL)
elexxion AG (E8X.DE)
NeuroMetrix, Inc. (NURO)
Anteris Technologies Ltd (AVR.AX)
Business
Ambu A/S develops, manufactures and markets single-use medical devices for endoscopy solutions and anesthesia & patient monitoring to hospitals, clinics, private practices and emergency services worldwide. The company offers a comprehensive portfolio of single-use endoscopes across pulmonology (including aScope Broncho), urology (including aScope Cysto), ear-nose-throat (including RhinoLaryngo) and gastroenterology (including aScope Gastro); video laryngoscopes such as SureSight Connect; airway management products including the Ambu Bag self-inflating resuscitator, laryngeal masks and ventilation devices; and diagnostic electrodes such as BlueSensor and Neuroline for ECG and neurophysiological monitoring. Founded in 1937 and headquartered in Ballerup, Denmark, Ambu operates production facilities in the US, China, Malaysia and Mexico, with sales in more than 100 countries and North America accounting for over 50% of revenue. In September 2025, the company launches its ZOOM AHEAD strategy, building on the successful ZOOM IN plan from 2022 by raising its five-year organic revenue growth target to 11-13% CAGR through FY 2029/30, targeting 15-20% growth in Endoscopy Solutions, and aspiring to global leadership in single-use endoscopy while planning acquisitions in 2025/26; it also earns Frost & Sullivan's 2025 Technology Innovation Leadership Recognition for its advancements in the European single-use endoscopy market.

Company News

APIChatGPT

  • defenseworld.net

    Ambu A/S (OTCMKTS:AMBBY) Sees Large Volume Increase – What’s Next?

  • defenseworld.net

    Ambu A/S (OTCMKTS:AMBBY) Trading 3.4% Higher – Still a Buy?